ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0023

Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Abstract Number: 1728

Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study
Abstract Number: 0297

Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
Abstract Number: 1644

Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis
Abstract Number: 2626

Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)
Abstract Number: 0909

Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
Abstract Number: 0597

Low 25-hydroxyvitamin D Levels are Associated with Higher Mortality and More Cardiovascular Events in Systemic Lupus Erythematosus
Abstract Number: 0444

Low Disease Activity: Good Enough?
Abstract Number: 1543

Low-Dose Aspirin Therapy in Patients with Type 2 Diabetes and Systemic Lupus Erythematosus: A Propensity-Matched Cohort Study
Abstract Number: 0656

Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
Abstract Number: 0540

Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease
Abstract Number: 1920

Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis
Abstract Number: 1193

Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Abstract Number: 2259

Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis
Abstract Number: 1255

Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].